Our meta-analysis found that LRRK2 G2019S decreased the risk and severity of RBD [21, 22, 27, 29–34], but LRRK2 G2385R did not affect the risk of RBD in patients with PD [25, 26, 28, 36]. Here, LRRK2 is linked to Parkinson disease.